» Articles » PMID: 15537676

Ketamine Disrupts Frontal and Hippocampal Contribution to Encoding and Retrieval of Episodic Memory: an FMRI Study

Overview
Journal Cereb Cortex
Specialty Neurology
Date 2004 Nov 13
PMID 15537676
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine produces episodic memory deficits. We used functional magnetic resonance imaging to characterize the effects of ketamine on frontal and hippocampal responses to memory encoding and retrieval in healthy volunteers using a double-blind, placebo-controlled, randomized, within-subjects comparison of two doses of intravenous ketamine. Dissociation of the effects of ketamine on encoding and retrieval processes was achieved using two study-test cycles: in the first, items were encoded prior to drug infusion and retrieval tested, during scanning, on drug; in the second, encoding was scanned on drug, and retrieval tested once ketamine plasma levels had declined. We additionally determined the interaction of ketamine with the depth of processing that occurred at encoding. A number of effects upon task-dependent activations were seen. Overall, our results suggest that left frontal activation is augmented by ketamine when elaborative semantic processing is required at encoding. In addition, successful encoding on ketamine is supplemented by additional non-verbal processing that is incidental to task demands. The effects of ketamine at retrieval are consistent with impaired access to accompanying contextual features of studied items. Our findings show that, even when overt behaviour is unimpaired, ketamine has an impact upon the recruitment of key regions in episodic memory task performance.

Citing Articles

Effects of Ketamine on Frontoparietal Interactions in a Rule-Based Antisaccade Task in Macaque Monkeys.

Ma L, Katyare N, Johnston K, Everling S J Neurosci. 2024; 44(50).

PMID: 39472063 PMC: 11638814. DOI: 10.1523/JNEUROSCI.1018-23.2024.


Neuroimaging features of cognitive impairments in schizophrenia and major depressive disorder.

Li Y, Zhang C, Han J, Shang Y, Chen Z, Cui G Ther Adv Psychopharmacol. 2024; 14:20451253241243290.

PMID: 38708374 PMC: 11070126. DOI: 10.1177/20451253241243290.


Pre-adolescence repeat exposure to sub-anesthetic doses of ketamine induces long-lasting behaviors and cognition impairment in male and female rat adults.

Behrooz A, Nasiri M, Adeli S, Jafarian M, Pestehei S, Fahanik Babaei J IBRO Neurosci Rep. 2024; 16:211-223.

PMID: 38352700 PMC: 10862408. DOI: 10.1016/j.ibneur.2024.01.005.


Esketamine-induced post-traumatic stress disorder flashbacks during treatment-resistant depression indication: is it just a side effect?.

Rotharmel M, Mekaoui L, Kazour F, Herrero M, Beetz-Lobono E, Lengvenyte A medRxiv. 2024; .

PMID: 38293161 PMC: 10827260. DOI: 10.1101/2024.01.09.24300998.


Targeting NMDA Receptor Complex in Management of Epilepsy.

Sivakumar S, Ghasemi M, Schachter S Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297409 PMC: 9609646. DOI: 10.3390/ph15101297.


References
1.
Olney J, Farber N . Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995; 52(12):998-1007. DOI: 10.1001/archpsyc.1995.03950240016004. View

2.
Lahti A, Holcomb H, Medoff D, Tamminga C . Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 1995; 6(6):869-72. DOI: 10.1097/00001756-199504190-00011. View

3.
Malhotra A, Pinals D, Weingartner H, Sirocco K, Missar C, Pickar D . NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996; 14(5):301-7. DOI: 10.1016/0893-133X(95)00137-3. View

4.
Tamminga C, Holcomb H, Gao X, Lahti A . Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol. 1995; 10 Suppl 3:29-37. View

5.
Fletcher P, Shallice T, Frith C, Frackowiak R, Dolan R . Brain activity during memory retrieval. The influence of imagery and semantic cueing. Brain. 1996; 119 ( Pt 5):1587-96. DOI: 10.1093/brain/119.5.1587. View